Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cencora (GB:0HF3)
LSE:0HF3
Cencora (0HF3) Share Price & Analysis
0 Followers
0HF3 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$162.76 - $246.93
Previous Close$238.8
Volume306.00
Average Volume (3M)969.00
Market Cap
$47.25B
Enterprise Value$49.30B
Total Cash (Recent Filing)$2.87B
Total Debt (Recent Filing)$4.78B
Price to Earnings (P/E)26.0
Beta0.47
Next Earnings
May 01, 2024EPS Estimate
$3.71Next Dividend Ex-DateN/A
Dividend Yield0.83%
Share Statistics
EPS (TTM)9.18
Shares Outstanding199,481,993
10 Day Avg. Volume21
30 Day Avg. Volume969
Standard Deviation0.07
R-Squared0.02
Alpha0.00406
Financial Highlights & Ratios
Price to Book (P/B)-3.63
Price to Sales (P/S)0.30
Price to Cash Flow (P/CF)13.50
P/FCF Ratio14.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.19
Enterprise Value/Gross Profit5.50
Enterprise Value/Ebitda18.23
Forecast
1Y Price Target
$258.20Price Target Upside8.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Cencora News
PremiumCompany Announcements
Cencora Announces CEO Change, Reaffirms 2024 Financial Outlook
PremiumCompany Announcements
Cencora Significant Share Sale Alters Ownership StakePremiumCompany Announcements
Cencora Buys Back Shares to Boost Shareholder ValueBulls Say, Bears Say
Bulls Say
Financial GuidanceThe company has reaffirmed its fiscal 2024 financial guidance, signaling confidence in its ability to meet or exceed financial targets.
Leadership TransitionCEO Steven Collis to transition to Executive Chair and COO Robert 'Bob' Mauch to become President and CEO, promising a smooth leadership change with a seasoned executive at the helm.
Market PositionCencora is poised to benefit from significant growth in specialty pharmaceuticals, with investments in its specialty platform expected to yield substantial returns.
Bears Say
International Market PerformanceInternational performance has been choppy and offers lower visibility than the U.S. market.
Stock Price OutlookThe current stock price premium is acknowledged, but further multiple expansion is not anticipated.
Stock ValuationRisk/reward is seen as balanced due to the stock's significant outperformance, suggesting limited upside potential.
---
Options Prices
Currently, No data available
---
Ownership Overview
15.57% Insiders
26.83% Mutual Funds
22.80% Other Institutional Investors
34.80% Public Companies and
Individual Investors
0HF3 FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest share price was $162.76 and its highest was $246.93 in the past 12 months.
What is Cencora’s market cap?
Currently, no data Available
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is May 01, 2024 which is in 7 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on Jan 31, 2024. The company reported $3.28 earnings per share for the quarter, beating the consensus estimate of $2.896 by $0.384.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora does not currently pay dividends.
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is $3.71.
How many shares outstanding does Cencora have?
Cencora has 199,482,000 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of $3.28 in its last earnings report, beating expectations of $2.896. Following the earnings report the stock price went up 4.467%.
Which hedge fund is a major shareholder of Cencora?
Among the largest hedge funds holding Cencora’s share is Antipodes Partners Ltd. It holds Cencora’s shares valued at 125M.
---
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$258.20 (8.12% Upside)
$258.20 (8.12% Upside)
Blogger Sentiment
Bullish
GB:0HF3 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $991.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.51%
12-Months-Change
Fundamentals
Return on Equity
509.03%
Trailing 12-Months
Asset Growth
11.71%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. engages provision of pharmaceutical products and business solutions that improve access
to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical
Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic
pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded
sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and
health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate
site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and
includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.
---
0HF3 Company Deck
---
0HF3 Earnings Call
Q1 2024
0:00 / 0:00
---
0HF3 Stock 12 Months Forecast
Average Price Target
$258.20
▲(8.12% Upside)
Technical Analysis
Best Analysts Covering 0HF3
1 Year
1 Year Success Rate
16/17 ratings generated profit
1 Year Average Return
+20.38%
reiterated a buy rating 3 months ago
Copying Kevin Caliendo's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +20.38% per trade.
---